This week, we’ll discuss the findings of a trial that examined the efficacy of intensified therapy for patients with newly diagnosed locally advanced rectal cancer. Then, we’ll talk about the FDA’s approval of a new agent for advanced endometrial cancer.

Coverage of stories discussed this week on ascopost.com:

Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer

FDA Grants Accelerated Approval to Dostarlimab-gxly for dMMR Endometrial Cancer

To listen to more podcasts from ASCO, visit asco.org/podcasts.